Leaflet PURI-NETHOL 50mg tablets


Indicated for: leukemia

Route of administration: oral

Substance: mercaptopurine (antimetabolite antineoplastic)

ATC: L01BB02 (Antineoplastic and immunomodulating agents | Antimetabolites | Purine analogues)

Mercaptopurine is a medication used for the treatment of acute lymphoblastic leukemia and other hematological conditions. It works by inhibiting DNA synthesis in cancer cells, thereby preventing their proliferation.

The medication is taken orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor liver and hematologic function.

Patients should be aware of potential side effects, such as nausea, decreased blood cell counts, or liver impairment. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, decreased blood cell counts, and liver impairment. In rare cases, severe reactions such as liver failure or severe infections may occur. Patients should be informed of these risks before use.

General data about PURI-NETHOL 50mg

  • Substance: mercaptopurine
  • Date of last drug list: 01-05-2026
  • Commercial code: W58868001
  • Concentration: 50mg
  • Pharmaceutical form: tablets
  • Quantity: 25
  • Product type: original
  • Price: 67.74 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: EXCELLA GMBH & CO. KG - GERMANIA
  • Holder: ASPEN PHARMA TRADING LIMITED - IRLANDA
  • Number: 11277/2018/01
  • Shelf life: 5 years

Pharmaceutical forms available for mercaptopurine

Concentrations available for mercaptopurine

  • 20mg/ml
  • 50mg

Compensation lists for PURI-NETHOL 50mg Aspen

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

67.74 RON

67.74 RON

0.00 RON